2
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Breast Neoplasms
48
Neoplasms
43
Depression
31
Fatigue
30
Prostatic Neoplasms
23
Precursor Cell Lymphoblastic Leukemia-Lymphoma
20
Lymphoma, Follicular
18
Multiple Myeloma
16
Lymphoma, Large B-Cell, Diffuse
16
Carcinoma, Non-Small-Cell Lung
16
Lymphoma, Non-Hodgkin
15
Lung Neoplasms
15
Leukemia, Lymphocytic, Chronic, B-Cell
15
Lymphoma, Mantle-Cell
14
Leukemia, Myeloid, Acute
14
Hodgkin Disease
14
Colorectal Neoplasms
14
Burkitt Lymphoma
14
Anxiety Disorders
14
Pain
13
Lymphoma, B-Cell, Marginal Zone
13
Lymphoma, Large-Cell, Immunoblastic
12
Lymphoma
11
Leukemia, Myeloid, Chronic-Phase
11
Head and Neck Neoplasms
11
Blast Crisis
11
Lymphoma, T-Cell, Cutaneous
10
Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative
10
Leukemia, Myeloid, Accelerated Phase
10
Leukemia, Hairy Cell
10
Interventions
Drug Therapy
3
Temozolomide
2
Radiotherapy
2
Radiosurgery
2
Leucovorin
2
Irinotecan
2
Fluorouracil
2
sacubitril and valsartan sodium hydrate drug combination
1
icotinib
1
dostarlimab
1
beta Carotene
1
avelumab
1
alpha-Tocopherol
1
Varenicline
1
Tyrosine Kinase Inhibitors
1
Trastuzumab
1
Tobacco Use Cessation Devices
1
Therapeutics
1
Thalidomide
1
Surveys and Questionnaires
1
Surgical Procedures, Operative
1
Semen Analysis
1
Registries
1
Probiotics
1
Patient Reported Outcome Measures
1
Panitumumab
1
Nicotine Chewing Gum
1
Myofascial Release Therapy
1
Megestrol Acetate
1
Lenalidomide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Second Primary
×
Therapeutics
×
Clear all
NCT03313193
2019-10-11
ACT-CC
University of California, San Francisco
Phase NA
Completed
95 enrolled